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Abstract
The EFSA Panel on Contaminants in the Food Chain (CONTAM) reviewed new studies on nivalenol
since the previous opinion on nivalenol published in 2013, but as no new relevant data were identiﬁed
the tolerable daily intake (TDI) for nivalenol (NIV) of 1.2 lg/kg body weight (bw) established on bases
of immuno- and haematotoxicity in rats was retained. An acute reference dose (ARfD) of 14 lg/kg bw
was established based on acute emetic events in mink. The only phase I metabolite of NIV identiﬁed is
de-epoxy-nivalenol (DE-NIV) and the only phase II metabolite is nivalenol-3-glucoside (NIV3Glc).
DE-NIV is devoid of toxic activity and was thus not further considered. NIV3Glc can occur in cereals
amounting up to about 50% of NIV. There are no toxicity data on NIV3Glc, but as it can be assumed
that it is hydrolysed to NIV in the intestinal tract it should be included in a group TDI and in a group
ARfD with NIV. The uncertainty associated with the present assessment is considered as high and it
would rather overestimate than underestimate any risk.
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Summary
Following a request from the European Commission, the EFSA Panel on Contaminants in the Food
Chain (CONTAM) assessed whether it is appropriate and feasible to set a group health based guidance
value (group HBGV) for nivalenol (NIV) and its modiﬁed forms related to their presence in food and
feed, and to consider, whether it would be appropriate to use the parent compound as a marker for
toxicity.
Modiﬁed forms of mycotoxins comprise all metabolites of the parent molecule, which are formed in
the fungus, infested plant and animals. It is increasingly realised that not only the parent mycotoxins
but also their modiﬁed forms may contribute to the overall toxicity. Modiﬁed forms include phase I
metabolites formed through oxidation, reduction or hydrolysis of the parent toxin, as well as phase II
metabolites arising from conjugation with endogenous molecules.
Previous risk assessments from EFSA on NIV and on modiﬁed mycotoxins have been used as a
starting point for the present assessment. In addition, a systematic literature search has been carried
out to obtain up-to-date and comprehensive information on NIV and its modiﬁed forms. In this
opinion, the general principles for risk assessment were followed. Before assessing whether modiﬁed
forms of NIV can be included in a group HBGV for NIV, the CONTAM Panel decided to review new
relevant data on NIV and its modiﬁed forms published after the European Food Safety Authority
(EFSA) assessment on NIV in 2013 to evaluate whether the established tolerable daily intake (TDI) for
NIV needed to be revised and if in addition there was a need also to set an acute reference dose
(ARfD) for NIV.
NIV is a member of the type B group trichothecenes, which are tetracyclic sesquiterpenoids
produced by many species of Fusarium infesting crop plants. To date, the only phase I metabolite of
NIV identiﬁed is de-epoxy-nivalenol (DE-NIV) and the only phase II metabolite identiﬁed is nivalenol-3-
glucoside (NIV3Glc). It can be expected, however, that other conjugated metabolites may be formed
in plants and fungi. Because of a lack of signiﬁcant toxicity, DE-NIV was not further considered in the
assessment.
Analytical methods (mainly based on liquid chromatography–tandem mass spectrometry (LC–MS/MS))
for NIV and NIV3Glc are available, but due to high polarity of both compounds recovery rates are often
affected by matrix effects. This may lead to poor recovery. Standards and reference materials are not
commercially available for modiﬁed forms of NIV. The higher polarity of NIV compared to other
trichothecenes makes analytical detection more difﬁcult under the same chromatographic conditions.
Further phase II metabolism would increase the polarity and thus conjugates would be even more
difﬁcult to analyse. It is, therefore, likely that there are other phase II metabolites of NIV not yet
identiﬁed.
NIV3Glc may occur in cereals amounting up to about 50% of its parent form. The transfer of NIV
from feed to food products of animal origin is expected to contribute only marginally to human
exposure.
NIV is rapidly absorbed, distributed and eliminated without accumulation. No NIV metabolites,
except DE-NIV, which is generated by biota in the rumen and also to some extent in the gut of
monogastric animals, have been identiﬁed in mammals. There are no in vivo data on the absorption of
NIV3Glc, but in vitro data indicate that it is not absorbed. In vitro data suggest that it is hydrolysed by
the gut microbiota and it may then be absorbed as NIV.
In vivo acute toxicity studies show that NIV has anorectic effects upon short-term exposure. Emetic
events observed upon single oral exposure to NIV in mink were identiﬁed as the critical acute effects
in the present assessment. In the previous opinion on NIV, it was concluded that there is no evidence
that other toxic effects occur at doses lower than those inducing immunotoxicity and haematotoxicity
and that there is no evidence for genotoxicity or carcinogenicity of NIV. De-epoxidation strongly
reduces toxicity of NIV. Albeit there is no toxicity information on NIV3Glc, it can be assumed that it is
hydrolysed to and absorbed in the lower intestinal tract as NIV.
It can be assumed that NIV induces anorexia by interfering with gut satiety peptide cholecystokinin.
NIV targets the ribosome leading to an inhibition of protein, RNA and DNA synthesis. Rapidly
proliferating tissues such as haematopoietic tissue are targets of NIV leading to leucopenia and
thrombocytopenia possibly due to induction of apoptosis.
The CONTAM Panel selected the emetic effects of NIV for the acute hazard characterisation.
Benchmark dose (BMD) analysis was performed on the incidence of emetic events in mink exposed to
NIV. The BMD modelling using a benchmark response (BMR) of 10% resulted in a benchmark dose
95% lower and upper conﬁdence interval (BMDL10–BMDU10) of 0.14–0.23 mg NIV/kg body weight
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(bw) per day. Using the acute BMDL10 of 0.14 mg/kg bw for NIV and an uncertainty factor of 10 for
intraspecies differences, an ARfD of 14 lg NIV/kg bw was established. No interspecies variability factor
was applied because humans were not considered more sensitive than mink to the acute emetic effect
of NIV, an assumption supported by studies on emesis with emetine showing that similar doses of the
compound are effective both in humans and mink. There are no data on acute emetic effects of
NIV3Glc but it is assumed that it will be hydrolysed in the lower intestine releasing NIV. Therefore,
NIV3Glc should be included in a group ARfD with NIV with the same molar potency factor (i.e. 1).
No new studies relevant for chronic hazard characterisation were identiﬁed since publication of the
previous opinion on NIV in 2013. Therefore, the BMDL05 of 0.35 mg NIV/kg bw per day based on a
reduction in white blood cell counts in a 90-day rat study as set in the previous opinion on NIV has
been retained for the present assessment and the TDI of 1.2 lg NIV/kg bw established in 2013 has
been retained. Because NIV3Glc can be hydrolysed to NIV after ingestion, it can be included in a
group TDI with NIV with the same molar potency factor (i.e. 1).
The currently established analytical methods might not be adequate for detection of polar
conjugates of NIV. Therefore, methods should be developed for accurate detection of NIV and its
modiﬁed forms to identify potential NIV metabolites not yet detected. Certiﬁed reference materials and
standards for the modiﬁed forms of NIV are also needed. Because there is no information available on
the toxicokinetics of modiﬁed forms of NIV, toxicokinetic studies, in particular with NIV3Glc should be
conducted.
Fusarenon-X (FUS-X) is not only a mycotoxin on its own, but also a precursor of NIV, and it
frequently co-occurs with NIV. Therefore, it might be appropriate to perform a hazard characterisation
of FUS-X and to evaluate whether or not it should be included in group HGBVs with NIV.
Group HBGV for nivalenol and its modiﬁed forms
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1. Introduction
1.1. Background Terms of Reference as provided by the requestor
Following a request from the European Commission, the risks to human and animal health related
to modiﬁed forms of the Fusarium toxins zearalenone, nivalenol, T-2 and HT-2 toxins, and fumonisins
were evaluated in the scientiﬁc opinion on the risks for human health related to the presence of
modiﬁed forms of certain mycotoxins in food and feed,1 adopted by the EFSA Panel on Contaminants
in the Food Chain (CONTAM) on 25 November 2014.
The CONTAM Panel considered it appropriate to assess human exposure to modiﬁed forms of the
various toxins in addition to the parent compounds, because many modiﬁed forms are hydrolysed into
the parent compounds or released from the matrix during digestion. In the absence of speciﬁc toxicity
data, toxicity equal to the parent compounds was assumed for modiﬁed mycotoxins. Risk characterisation
was done by comparing exposure scenarios with reference doses of the parent compounds.
The regulatory follow-up to this scientiﬁc opinion was discussed at the Expert Committee
‘Agricultural contaminants’ on 15 January 2015. The Standing Committee on Plants, Animals, Food and
Feed has been informed thereof at its meeting on 11 February 2015.2
Before taking regulatory measures as regards the modiﬁed mycotoxins, it was agreed that it is
appropriate to request EFSA to assess whether it is appropriate and feasible to set a group health
based guidance value (group HBGV) for the parent compound and its modiﬁed forms and to consider,
if relevant, the appropriateness to use the parent compound as a marker for the presence and toxicity
of the parent compound and its modiﬁed forms.
1.2. Terms of Reference as provided by the requestor
In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002, the Commission asks European
Food Safety Authority (EFSA) for scientiﬁc opinions to assess whether it is appropriate and feasible to
set a group HBGV for the parent compound and its modiﬁed forms for zearalenone, fumonisins,
nivalenol, and T-2 and HT-2 toxins and to consider, if relevant, the appropriateness to use the parent
compound as a marker for the presence and toxicity of the parent compound and its modiﬁed forms
for these mycotoxins.
The four requested scientiﬁc opinions are:
1) assessment whether it is appropriate and feasible to set a group HBGV for zearalenone and
its modiﬁed forms identiﬁed in the CONTAM opinion on the risks for human health related to
the presence of modiﬁed forms of certain mycotoxins in food and feed, and to consider, if
relevant, the appropriateness to use the parent compound as a marker for the presence and
toxicity of zearalenone and its modiﬁed forms.
2) assessment whether it is appropriate and feasible to set a group HBGV for fumonisin B1 and
B2 and their modiﬁed forms identiﬁed in the CONTAM opinion on the risks for human health
related to the presence of modiﬁed forms of certain mycotoxins in food and feed and to
consider, if relevant, the appropriateness to use the parent compounds as a marker for the
presence and toxicity of fumonisin B1 and B2 and their modiﬁed forms.
3) assessment whether it is appropriate and feasible to set a group HBGV for nivalenol and its
modiﬁed forms identiﬁed in the CONTAM opinion on the risks for human health related to
the presence of modiﬁed forms of certain mycotoxins in food and feed and to consider, if
relevant, the appropriateness to use the parent compound as a marker for the presence and
toxicity of nivalenol and its modiﬁed forms.
4) assessment whether it is appropriate and feasible to set a group HBGV for T-2 and HT-2
toxins and their modiﬁed forms identiﬁed in the CONTAM opinion on the risks for human
health related to the presence of modiﬁed forms of certain mycotoxins in food and feed and
to consider, if relevant, the appropriateness to use the parent compound as a marker for the
presence and toxicity of T-2 and HT-2 toxins and their modiﬁed forms.
1 EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2014. Scientiﬁc Opinion on the risks for human and
animal health related to the presence of modiﬁed forms of certain mycotoxins in food and feed. EFSA Journal 2014;
12(12):3916, 107 pp. doi:10.2903/j.efsa.2014.3916 Available online: www.efsa.europa.eu/efsajournal
2 Summary report of the Standing Committee on Plants, Animals, Food and Feed, held in Brussels on 11 February 2015
(Section Toxicological Safety of the Food Chain), agenda item A.06. Report available at: http://ec.europa.eu/food/committees/
regulatory/scfcah/toxic/docs/sum_20150211_en.pdf
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1.3. Introduction to modiﬁed mycotoxins
Mycotoxins are secondary metabolites of ﬁlamentous fungi. They are usually low molecular weight
compounds and serve no function in the intermediary metabolism of the fungus, but provide
advantages with respect to its competition for nutrients and habitat. Consequently, many mycotoxins
are toxic for bacteria and other microorganisms. As mycotoxins are also toxic for humans and animals,
their presence in food and feed may pose a health risk.
Numerous mycotoxins have been characterised. Even though some of these may be metabolites of
the other, they are recognised as separate mycotoxins. However, it is increasingly realised that also
modiﬁed forms of these mycotoxins occur in food and feed and that these modiﬁed forms should be
taken into account for risk assessment, because they may contribute to the toxicity of the parent toxin.
According to a recent deﬁnition, modiﬁed forms of mycotoxins comprise all biologically, chemically
and physically modiﬁed derivatives of the parent molecule, which are formed in the fungus, infested
plant and mammalian organism (Rychlik et al., 2014). This includes inter alia phase I metabolites
formed through oxidation, reduction or hydrolysis of the parent toxin, as well as phase II metabolites
arising from conjugation with endogenous molecules. Phase II metabolites formed in the plant through
conjugation with polar low molecular weight molecules such as glucose or sulfate have also been called
‘masked’ mycotoxins because they were hard to capture by routine analysis (Rychlik et al., 2014).
However, after intake with the food or feed such conjugates may be hydrolysed in the digestive tract,
thereby releasing the parent toxin which may add to the total uptake of toxin. Therefore, phase II
metabolism in the plant or fungi is of paramount importance for the risk assessment of mycotoxins.
In the context of risk assessment of mycotoxins in food and feed, modiﬁed mycotoxins comprise all
metabolites of a given mycotoxin that occur in food or feed. These include phase I and II metabolites
formed in the fungus, infested plant used for food and feed or food (and feed) products of animal
origin. It does not include metabolites formed in humans, even if these may be similar.
1.4. Legislation
Article 2 of Council Regulation (EEC) No 315/933 stipulates that food containing a contaminant in
an amount unacceptable for public health shall not be placed on the market, that contaminant levels
should be kept as low as can reasonably be achieved and that, if necessary, the European Commission
may establish maximum levels for speciﬁc contaminants. These maximum levels are laid down in the
Annex of Commission Regulation (EC) No 1881/20064 and may include maximum levels (MLs) for the
same contaminants in different foods, analytical detection limits and reference to the sampling and
analysis methods to be used. Neither for nivalenol nor for nivalenol metabolites have MLs have been
set in the regulation.
1.5. Interpretation of Terms of Reference
The CONTAM Panel took the assumption that the previous risk assessment of nivalenol in food and
feed (EFSA CONTAM Panel, 2013) is comprehensively covering all relevant aspects of the compound
and therefore used it together with the recent opinion on modiﬁed mycotoxins (EFSA CONTAM Panel,
2014) as a starting point for the present assessment.
The CONTAM Panel decided to review the new relevant data on nivalenol (i.e. that published after
2012) to evaluate whether the tolerable daily intake (TDI) established for nivalenol in 2013 needs to
be revised and if in addition there is a need also to set an acute reference dose for nivalenol.
The Panel decided to address the modiﬁed forms of nivalenol identiﬁed to date and reviewed the
appropriateness of the methods currently available for their analysis.
In line with the previous EFSA opinion on modiﬁed mycotoxins (EFSA CONTAM Panel, 2014),
modiﬁed nivalenol occurring in plants (arising from both plant and fungal metabolism), formed as a
consequence of food processing and transfer from feed to livestock were considered for possible
inclusion in group HBGVs.
In order to assess whether it was appropriate to include the modiﬁed forms of nivalenol in group
HBGVs with nivalenol, all data available and relevant for that task were evaluated.
3 Council Regulation (EEC) No 315/93 of February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–5.
4 Regulation (EC) No 1881/2006 of the European Parliament and the Council of 19 December 2006 setting maximum levels for
certain contaminants in foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
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2. Data and methodologies
2.1. Methodology for data collection and study appraisal
The CONTAM Panel considered the previous assessments on nivalenol (EFSA CONTAM Panel, 2013)
and on modiﬁed mycotoxins that included modiﬁed nivalenol (EFSA CONTAM Panel, 2014) as
comprehensive, covering all relevant publications on nivalenol and its modiﬁed forms, respectively, until
those dates. All publications referenced therein have been considered, wherever appropriate, also for
the present evaluation.
In order to cover also new publications not considered in these previous assessments, a systematic
and comprehensive search for literature was conducted for peer-reviewed original research pertaining to
nivalenol and its modiﬁed forms published after 2012 including scientiﬁc literature dealing with analytical
determination, chemistry, occurrence, toxicokinetics and toxicity of nivalenol and/or its modiﬁed forms.
Studies on analytical methods, chemistry and occurrence of the parent compound nivalenol only,
however, were excluded because not considered of relevance for the present assessment.
Date, search strings, databases used and numbers of publications retrieved and used for
assessment are presented in detail in Appendix A. In total, 371 citations/abstracts were obtained.
Those considered relevant by expert judgement were included in the present assessment. Only papers
in English language were considered for inclusion in the assessment.
During the development of the opinion, additional relevant studies published until January 2017 and
not retrieved in the above-mentioned literature evaluation have been identiﬁed and considered for the
assessment when relevant.
2.2. Methodology applied for hazard assessment
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO/IPCS (2009), which include hazard identiﬁcation and characterisation,
exposure assessment and risk characterisation. In addition to the principles described by WHO/IPCS
(2009), any EFSA guidance pertaining to risk assessment and relevant for the present assessment has
been duly considered for the present assessment.
3. Previous assessments
A comprehensive risk assessment of NIV in food and feed was published in 2013 (EFSA CONTAM
Panel, 2013). In this opinion, immunotoxicity and haematotoxicity were identiﬁed as the critical effects
of NIV for the allocation of a TDI. In an oral 90-day rat study, effects such as neutropenia, leucopenia,
erythropenia and thrombocytopenia were observed. The decrease in white blood cell (WBC) count was
identiﬁed as the most appropriate endpoint for benchmark dose (BMD) modelling. The 95% lower
conﬁdence limit for the benchmark dose response of 5% extra risk (BMDL05) was calculated based on
combined data for male and female animals and was 0.35 mg NIV/kg body weight (bw) per day.
Applying a default uncertainty factor (UF) of 100 for inter- and intraspecies differences and an
additional UF of 3 for gaps in the database on NIV to the BMDL05, a TDI of 1.2 lg/kg bw was
established for NIV.
In 2014, a risk assessment on human and animal health related to the presence of modiﬁed forms
of certain mycotoxins in food and feed was carried out (EFSA CONTAM Panel, 2014). In this opinion,
no speciﬁc information on the toxic effects of the modiﬁed forms of NIV could be identiﬁed. However,
the chemistry and toxicokinetics of NIV as well as general considerations of biotransformation
suggested that NIV conjugates may be cleaved in the gastrointestinal tract releasing NIV. Taking a
pragmatic approach until more information became available, the CONTAM Panel assumed that
modiﬁed forms of NIV have the same toxicological proﬁle and potency as their parent compounds.
Based on occurrence data available at that time (2014), it was then assumed that modiﬁed forms of
NIV add another 30% to the exposure to NIV.
4. Chemistry
NIV (Figure 1) is a member of the trichothecene family, which represents the largest group of
Fusarium mycotoxins and comprises more than 150 compounds. The common structure of all
trichothecenes is a tetracyclic sesquiterpene with a spiro-epoxide group at C-12 and C-13, and an
oleﬁnic double bond between C-9 and C-10. According to the substituents of the tetracyclic ring
Group HBGV for nivalenol and its modiﬁed forms
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system, trichothecenes are grouped into four different types (A–D). Type A and B compounds
constitute the majority of trichothecene contaminants in food and feed. Typical type A trichothecenes
are characterised by an unsubstituted C-8 position or an esteriﬁed or free hydroxyl group at C-8, e.g.
diacetoxyscirpenol, T-2 toxin or neosolaniol, respectively. Nivalenol belongs to the type B
trichothecenes, all of which carry a keto group at C-8. Other typical type B trichothecenes are
deoxynivalenol and fusarenon-X (Figure 1). Fusarenon-X (FUS-X, 4-acetylnivalenol) is the biosynthetic
precursor of nivalenol (see below). Deoxynivalenol (DON), which is not a nivalenol metabolite but a
mycotoxin in its own right, must not be confused with de-epoxy-nivalenol (DE-NIV), which is a phase I
metabolite of NIV as it is also a deoxy derivative (see below).
The biosynthesis of trichothecenes involves the initial cyclisation of farnesyl phosphate to the
bicyclic sesquiterpene trichodiene, which does not contain oxygen, followed by a complex sequence of
hydroxylation, epoxidation, further cyclisation, and acylation reactions (for review, see McCormick
et al., 2011). NIV arises through hydrolysis of the 4-acetoxy group of its biosynthetic precursor FUS-X.
In general, microorganisms, plants, and animals may biotransform mycotoxins by phase I metabolic
pathways, which include oxidation, reduction and hydrolysis of the parent (fungal) compounds, and by
phase II metabolism, which comprises all conjugation reactions. Although phase II metabolites formed
in the mammalian organism are usually excreted via urine and/or bile, plants store conjugated
metabolites in vacuoles and/or attach them to structures of the cell wall. The latter processes are
sometimes referred to as phase III metabolism or compartmentation.
4.1. Parent compound and metabolites
NIV has the IUPAC name 3a,4b,7a,15-tetrahydroxy-12,13-epoxytrichothec-9-en-8-one (CAS No.
23282-20-4, C15H20O7, MW 312). It is a colourless crystalline powder with a melting point (m.p.) of
222–223°C, and was ﬁrst isolated from cultures of Fusarium nivale strain Fn2B and given the name
nivalenol by Tatsuno et al. (1968).
The solubility of NIV is low in water and petroleum ether, but good in organic solvents of medium
to high polarity (EFSA CONTAM Panel, 2013). Solutions of NIV in acetonitrile are stable for at least
24 months at temperatures up to 25°C, whereas solutions in ethyl acetate are only stable for up to
one year if kept at 0°C (Widestrand and Pettersson, 2001). The maximum UV absorption of NIV in
acetonitrile is at 220 nm with a molar absorptivity coefﬁcient of 6,955  205 L/mol (Sydenham et al.,
1996; Krska et al., 2007).
Figure 1: Chemical structures of nivalenol and related compounds
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Although NIV has a short trivial name, it is commonly abbreviated as NIV in the scientiﬁc literature.
This abbreviation is also used in this Opinion, mainly because it is of advantage for abbreviating the
more complex names of the phase II metabolites of NIV.
As discussed in more detail in Sections 6 and 7.3, only one phase I metabolite of NIV has been
identiﬁed. It is listed in Table 1 and its chemical structure is depicted in Figure 1. As NIV and its
metabolite lack a strong chromophore, the analytical method of choice is often liquid chromatography–
mass spectrometry (LC–MS) analysis, which has the advantage of an efﬁcient separation from complex
matrices and high sensitivity (see Section 5). Therefore, the element formulas and molecular weights
of NIV and its metabolites are given in Table 1.
De-epoxy-nivalenol (DE-NIV) has ﬁrst been isolated from the faeces of rats after oral administration
of NIV (Onji et al., 1989). The chemical structure has been elucidated by the same authors using mass
spectrometry (MS) as well as 1H and 13C nuclear magnetic resonance (NMR).
In general, most phase II metabolic pathways lead to the formation of water-soluble conjugates
through covalent binding of the parent compound or a phase I metabolite to a polar molecule, e.g. a
carbohydrate or sulfate, from the metabolising organism. In most cases, activation of the conjugating
moiety and a transferase enzyme are needed to form the covalent bond. Sulfate is used as conjugate
group by fungi, plants and animals. The major carbohydrate employed for conjugation by plants and
fungi is glucose, whereas animals use glucuronic acid. The glucose can be further modiﬁed in plants,
e.g. by esteriﬁcation with another hexose or with malonic acid. Moreover, plants can use acetate and
ferulate for conjugation. The major conjugating moieties in plants are depicted in Figure 2.
For the abbreviation of the carbohydrates and their modiﬁed forms used in phase II metabolism,
the same nomenclature as in the Scientiﬁc Opinion on the risks for human and animal health related to
the presence of modiﬁed forms of certain mycotoxins in food and feed (EFSA CONTAM Panel, 2014) in the
Scientiﬁc Opinion on the appropriateness to set a group-based guidance value for zearalenone and its
modiﬁed forms (EFSA CONTAM Panel, 2016), and in the Scientiﬁc Opinion on the appropriateness to
set a group-based guidance value for T-2 and HT-2 toxins and their modiﬁed forms (EFSA CONTAM
Panel, 2017) will be used. These abbreviations, which are common in carbohydrate chemistry, clearly
designate the speciﬁc carbohydrate (e.g. Glc for glucose, Man for mannose, Xyl for xylose) and its
oxidation state (e.g. GlcA for glucuronic acid). For a complete designation, also the type of ring (p for
pyranose or f for furanose), the conﬁguration (D or L), and the type of glycosidic bond (a or b) could
β
β β
β
Figure 2: Glucose (depicted in two different stereochemical representations), modiﬁed glucose, and
sulfate, feruloyl and acetyl groups used for the conjugation of mycotoxins in plants
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be given, if known. For further details, see Scientiﬁc Opinion on the risks for human and animal health
related to the presence of modiﬁed forms of certain mycotoxins in food and feed (EFSA CONTAM
Panel, 2014).
To date, the only reported phase II metabolite of NIV is its 3-O-b-D-glucopyranoside (NIV-3-b-Glc,
short form NIV3Glc, which is used in this opinion for the compound, Figure 3), which was isolated by
Yoshinari et al. (2014) from NIV-contaminated wheat and structurally identiﬁed by LC–MS and 1H and
13C NMR.
The fact that other modiﬁed forms of NIV have not yet been observed is probably due to the
scarcity of studies aiming at their disclosure in fungi, plants and animals. Because NIV has four
hydroxyl groups, it must be expected to undergo conjugation with sulfate, acetate and glucuronic acid,
as has been described for other trichothecenes such as DON and T-2 toxin (Wu et al., 2012). The
detection of such conjugates of NIV must be expected in future studies.
Concluding remarks
The only phase I metabolite of NIV identiﬁed is de-epoxy-NIV (DE-NIV). The only phase II
metabolite identiﬁed is NIV-3-b-Glc (NIV3Glc). It is expected that other conjugated metabolites of NIV
are formed in plants and fungi.
5. Analytical methods
There is a wide range of methods for analysis of NIV in the literature, which can be applied for
both food and feed, among them mainly grains. The CONTAM Panel has recently extensively reviewed
the analytical methods developed for NIV (EFSA CONTAM Panel, 2013); thus, this opinion will consider
only those methods published since 2013. The accurate quantiﬁcation of NIV is usually performed
together with DON and other major trichothecenes, using liquid chromatography–tandem mass
spectrometry (LC–MS/MS) with a multitoxin approach. Methods can be applied to food, feed and other
biological samples. As for other Fusarium mycotoxins, sample extraction is based on mixtures of
acetonitrile/water or methanol/water acidiﬁed with acetic or formic acid (Malachova et al., 2014;
Nathanail et al., 2015). Due to the higher polarity of NIV, it is strongly affected by matrix effects.
Therefore, although the sensitivity is often higher compared with other trichothecenes, recovery rates
are usually lower (Rubert et al., 2012; Capriotti et al., 2014; Malachova et al., 2014). Albeit the
common sample preparation is based on ‘dilute & shoot’ approach, cross-reactive immunoafﬁnity
columns made for DON are still in use for sample clean-up (Capriotti et al., 2014; Yang et al., 2015).
Similarly, dispersive solid-phase extraction (DSPE) and QuEChERS (quick, effective, cheap, rugged and
save) have been proposed as sample clean-up (Rubert et al., 2012; Zhao et al., 2014). Even if the
matrix effect was lowered, recovery rate for NIV was only about 60%.
Figure 3: Chemical structure of NIV-3-b-Glc
Table 1: Nivalenol and its metabolites
Compound(a) Element formula Molecular weight
NIV C15H20O7 312
DE-NIV C15H20O6 296
NIV-3-b-Glc C21H30O12 474
(a): DE: de-epoxy; Glc: glucose; NIV: nivalenol.
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Methods based on liquid chromatography photodiode array detection (LC-PDA), liquid
chromatography ﬂuorescence detection (LC-FLD) or gas chromatography–mass spectroscopy (GC–MS)
are still in use in control laboratories, although such protocols require extensive sample puriﬁcation
and/or a derivatisation step prior to the analysis. This affects signiﬁcantly the overall recovery and
sensitivity (Nardiello et al., 2014; Pascale et al., 2014; Rodrıguez-Carrasco et al., 2014; Trombete
et al., 2016).
In consideration of the little knowledge on modiﬁed forms of NIV, their detection is mainly based on
screening or semiquantitative LC–MS/MS methods, without properly optimised analytical parameters
(Nakagawa et al., 2011; Yoshinari et al., 2014). Such methods might be inadequate with regard to
recovery and sensitivity.
None of the currently available analytical methods for NIV and its modiﬁed forms has been fully
validated in interlaboratory studies. Calibrants are available on the market but not reference materials.
The higher polarity of NIV compared to other trichothecenes leads to a more difﬁcult analytical
detection under the same chromatographic conditions. Phase II metabolism would increase the
polarity and thus conjugates would be even more difﬁcult to analyse. Therefore ﬁt-for-purpose
methods should be designed for an accurate detection of NIV and its modiﬁed forms.
Due to the lack of antibodies speciﬁcally designed for NIV, no rapid immunochemical methods are
available. Cross-reactive antibodies designed for DON have been exploited for combined detection of
DON and NIV (Versilovskis et al., 2011; Polakowski et al., 2015), but their potential use for modiﬁed
forms has not been investigated.
6. Occurrence of nivalenol and its modiﬁed forms
In 2013, the CONTAM Panel extensively evaluated the occurrence of NIV in food commodities (EFSA
CONTAM Panel, 2013). As previously described, NIV occurs mainly in grains, in particular in maize, oats
and wheat. Most of the reports indicate the co-occurrence of NIV with DON and minor amounts of
other trichothecenes. Since then several publications have been identiﬁed by the CONTAM
Panel which generally conﬁrm the previous ones regarding the occurrence of NIV (Lindblad et al., 2013;
Rodrıguez-Carrasco et al., 2013, 2015; Alkadri et al., 2014; Covarelli et al., 2015; Beccari et al., 2016;
Gromadzka et al., 2016).
The CONTAM Panel did not identify any reports on occurrence of phase I metabolites of NIV, and
only few studies have been identiﬁed reporting occurrence of phase II conjugates.
A monoglucoside of NIV has been reported for the ﬁrst time in wheat grain that was artiﬁcially
infected with Fusarium fungi (Nakagawa et al., 2011). LC–MS was used for detection and did not allow
to elucidate the exact structure, i.e. position of the glucose moiety. According to the authors, more
than 15% of NIV was present as glucoside.
More recently, a glucoside of NIV has also been detected in wheat by Yoshinari et al. (2014) and
was identiﬁed as NIV3Glc using NMR. It accounted for 12–27% of the total NIV present in the wheat
samples.
The co-occurrence of NIV and NIV3Glc was reported in Finnish cereals by Nathanail et al. (2015).
The authors analysed barley (n = 34), oats (n = 31) and wheat (n = 30) harvested in 2015. In barley,
73% of the samples contained NIV and 62% contained NIV3Glc. Corresponding ﬁgures for oats where
71% and 16%, and those for wheat 43% and 10%, respectively. For NIV, the mean and maximum
concentrations were 96 and 302 lg/kg in barley, 635 and 4,940 lg/kg in oats, and 49 and 74 lg/kg in
wheat, respectively. Corresponding ﬁgures for NIV3Glc were 25 lg/kg (24% as compared with NIV)
and 65 lg/kg (22% as compared with NIV) in barley, 36 lg/kg (6% as compared with NIV) and
58 lg/kg (1.2% as compared with NIV) in oats, and 23 lg/kg (47% as compared with NIV) and
33 lg/kg (45% as compared with NIV) in wheat, respectively.
The CONTAM Panel noted that FUS-X, which is reported in the literature as a mycotoxin on its own,
is also a precursor in the fungal biosynthesis of NIV and frequently co-occurs with NIV.
The transfer of NIV from feed to food products of animal origin is expected to contribute only
marginally to human exposure.
7. Toxicokinetics of modiﬁed forms of nivalenol
Toxicokinetics of NIV have been reviewed in the previous opinion on NIV and rapid absorption,
distribution and excretion via faeces without accumulation was reported in a few studies using
experimental or farm animals (EFSA CONTAM Panel, 2013).
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7.1. Absorption
Generally, NIV was rapidly absorbed in all vertebrates investigated, i.e. rodents, pigs and poultry
(EFSA, CONTAM Panel, 2013) although new data (not considered in the previous opinion) show a low
bioavailability (4%) with a peak plasma concentration at 2.4 h after administration of a single oral
dose of 0.8 mg/kg bw to young chicken (Kongkapan et al., 2016a). No in vivo data are available on
the absorption of NIV3Glc but it has been shown in vitro that it is not efﬁciently transported through
intestinal epithelial cell monolayers (Gratz et al., 2017). However, based on in vitro data with bacteria
(Gratz et al., 2017), it can be assumed that NIV3Glc is hydrolysed in the large intestine, releasing its
aglycone, which can then be absorbed.
7.2. Distribution
The very limited studies regarding the tissue distribution of NIV (described in EFSA CONTAM Panel,
2013) show that NIV is distributed into tissues without accumulation and can also be transported into
fetal or suckling mice. In a recent publication, Kongkapan et al. (2016a) report that NIV reaches peak
concentrations in the liver, kidney, muscle and heart of broiler chicken 3 h after a single oral dose of
0.8 mg/kg bw, followed by a marked decline after 6 and 12 h; the plasma elimination half-life was
2.5 h.
7.3. Metabolism
De-epoxidation is the only phase I metabolic pathway of NIV known to date. DE-NIV has been
demonstrated in the faeces of rats, pigs and poultry, and it is assumed to be generated by the
gastrointestinal microﬂora (Wu et al., 2010; EFSA CONTAM Panel, 2013; Kongkapan et al., 2016b).
De-epoxidation is considered to be a detoxiﬁcation reaction as DE-NIV is much less toxic in vitro
compared with NIV (Eriksen et al., 2004).
7.4. Excretion
Upon multiple oral exposure of male Wistar rats to NIV, 80% of the total administered dose were
recovered from the faeces as DE-NIV and 7% as parent NIV; in urine, DE-NIV and NIV each accounted
for only 1% of the dose (Onji et al., 1989).
8. Toxicity
8.1. In vivo toxicity data on nivalenol
8.1.1. Study used for establishing the TDI by EFSA 2013
In its previous opinion (EFSA CONTAM Panel, 2013), the CONTAM Panel concluded that
immunotoxicity and haematotoxicity are the critical endpoints of NIV and that there is no evidence for
genotoxicity and carcinogenicity for NIV. The CONTAM Panel based its evaluation on a 90-day rat
dietary study where NIV was given at doses equivalent to 0.4, 1.5 and 6.9 mg/kg bw per day to male
rats and 0.4, 1.6 and 6.4 mg/kg bw per day to female rats (Sugita-Konishi et al., 2008; Takahashi
et al., 2008). A signiﬁcant decrease in the white blood cell (WBC) count was found at the highest dose
of 6.9 mg/kg bw per day in males and at all doses in females. In addition, at the highest dose,
decreased platelet counts in both sexes, decreased red blood cell counts in males and decreased
haemoglobin concentration in females were observed. Hypocellularity and decrease in haematopoietic
cell number in the bone marrow of femur and sternum at the highest dose was observed in most male
and female rats. The CONTAM Panel concluded in 2013 that the lowest dose of 0.4 mg/kg bw per day
tested in this study should be considered as the lowest-observed-adverse-effect-level (LOAEL) for NIV.
8.1.2. In vivo toxicity studies with NIV published after 2013
8.1.2.1. Acute toxicity
Mice
In order to evaluate acute anorectic effects groups of eight female mice were administered orally 0,
0.01, 0.1, 1 and 5 mg/kg bw NIV. After fasting, mice were given toxin and then immediately provided
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with pre-weighed food and food intake was measured after 2, 16, 24, 36, 48, 60 72 and 96 h. Only
after the ﬁrst 2 h was signiﬁcantly reduced feed uptake observed corresponding to 28% (1 mg/kg bw
NIV) and 44% (5 mg/kg bw) less food as compared with the negative control. Doses of 0.01 mg/kg
bw NIV had no effect and a slight decrease at 0.1 mg/kg bw NIV was not signiﬁcantly different. The
no-observed-adverse-effect-levels (NOAELs) and LOAELs identiﬁed by the authors for NIV were 0.1
and 1 mg/kg bw, respectively (Wu et al., 2012).
Mink
Female mink (six animals per group), were administered 0, 0.05, 0.1, 0.25 and 0.5 mg NIV/kg bw
by gavage (Wu et al., 2013). Animals were then monitored for emesis for 3 h during which the
incidence of emesis, latency to emesis, emesis duration and number of emetic events were recorded.
No emesis was observed in controls and the two lowest dose group, whereas doses of 0.25 and
0.5 mg/kg bw induced emesis in four out of six and in six out of six animals, respectively. According to
the authors, the NOAEL for emesis was 0.1 mg/kg bw per day and the corresponding LOAEL 0.25 mg/
kg bw per day. In the same study, minks were given NIV intraperitoneally (i.p.) at similar doses and
likewise emesis was observed, albeit already at slightly lower doses.
8.1.2.2. Subacute toxicity
Mice
Three-week-old ICR (an outbred mouse strain)-derived glomerulonephritis (ICGN) mice, a strain
that is sensitive to kidney effects, were not more susceptible to NIV than 3-week-old ICR mice or adult
animals when given oral doses of NIV equivalent to 0, 0.8, 1.6 and 3.2 mg/kg bw per day for 4 weeks,
suggesting, according to the authors that kidneys of infant mice are not sensitive to NIV under the
treatment conditions (Inoue et al., 2014).
8.1.3. In vitro toxicity studies with NIV published after 2013
New data on in vitro toxicity of NIV published since the last evaluation (EFSA CONTAM Panel, 2013)
conﬁrm previously known effects such as induction of apoptosis, cytotoxicity, increased secretion of
anti-haematopoietic macrophage inﬂammatory proteins, reduction of mitochondrial activity and
reduced cell proliferation (Wan et al., 2013a,b,c; Nagashima and Nakagawa, 2014; Park et al., 2014;
Cheat et al., 2015; Del Regno et al., 2015; Vejdovszky et al., 2016).
8.1.4. Genotoxicity studies with NIV published after 2013
Le Hegarat et al. (2014) carried out a battery of in vivo assays (Comet assay, micronucleus assay,
Pig-a assay) with NIV in a series of organs (duodenum, colon, blood, liver, spleen, kidney, bone
marrow). In addition in vitro Comet assays with TK6 (thymidine kinase heterozygous cell line) cells
were performed. The authors report consistently negative results from all investigations.
8.2. Toxicity data on modiﬁed forms of nivalenol
8.2.1. In vivo toxicity data
No relevant in vivo data have been identiﬁed by the CONTAM Panel.
8.2.2. In vitro toxicity data
Eriksen et al. (2004, cited also in EFSA CONTAM Panel, 2013) studied the cytotoxicity of NIV and
DE-NIV in 3T3 mouse ﬁbroblasts using the incorporation of bromodeoxyuridine (BrdU) into DNA. The
inhibitory concentration 50% (IC50) value for DE-NIV for DNA synthesis was 55 times higher than the
IC50 for NIV. The low in vitro toxicity of DE-NIV as compared with NIV suggests that de-epoxidation is
a strong detoxiﬁcation reaction.
9. Mode of action for toxicity of nivalenol and its modiﬁed forms
The possible mode of action of NIV toxicity has been discussed in the previous opinion on NIV
(EFSA CONTAM Panel, 2013) where only a few publications concerning its mode of action have been
presented. Similar to other trichothecenes, NIV targets the ribosome leading to an inhibition of
protein-, RNA- and DNA synthesis with inhibition of protein synthesis as the primary event. The
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ribosome binding activates mitogen-activated protein kinase (MAPK) via a mechanism known as the
‘ribotoxic stress response’. MAPKs are important transducers of downstream signalling events related to
immune response and apoptosis.
As the removal of the epoxy group strongly reduces toxicity of NIV, it can be assumed that the
epoxy group is central for the binding to the ribosomes, the initial key event in NIV toxicity. The key
role of the epoxide group for the binding to the A site of the ribosome peptidyl transferase centre is
generally assumed for type A and B trichothecenes and has recently been shown by molecular
modelling for DON (Pierron et al., 2016).
Rapidly proliferating tissues such as haematopoietic tissue are targets of NIV leading to leucopenia
and thrombocytopenia possibly due to induction of apoptosis (EFSA CONTAM Panel, 2013).
Using both pig jejunum explants and pig intestinal loops, Cheat et al. (2015) observed a 30%
decrease of proliferation after 4 h NIV exposure. NIV also increased apoptosis at the top of villi and
reduced by almost half the proliferative/apoptotic cell ratio. Lamina propria cells (mainly immune cells)
were more sensitive than enterocytes (epithelial cells) to apoptosis induced by NIV.
Recent data have also conﬁrmed the effects of NIV on inﬂammation. In vitro, NIV increased mRNA
expression of pro-inﬂammatory cytokines (IL1a, IL1b, IL8, TNFa and MCP-1) in the porcine jejunal
epithelial cell line IPEC-J2 (Wan et al., 2013b). In vivo, an acute oral exposure of mice to NIV induced
a transient splenic inﬂammatory response as measured by the mRNA expression of cytokines IL-1b,
CXCL-2, CCL-2 and CCL-7 (Wu et al., 2014a). This response was lower than the one observed with a
similar dose of DON.
As other trichothecene mycotoxins, NIV induced anorexia/emesis and growth suppression. The
mechanism underlying these effects is not fully understood. However, it was demonstrated that oral
increasing doses of NIV, administered by oral gavage, correlate with increased plasma concentrations
of the gut satiety peptides cholecystokinin (Wu et al., 2014b). This suggests a mechanism of action
similar to that of other trichothecenes such as DON and T2 (EFSA CONTAM Panel, 2017).
10. Dose–response analysis
10.1. Acute effects
As described in Section 8.1.2, Wu et al. (2013) dosed mink dosed orally with 0, 0.05, 0.1, 0.25 and
0.5 mg NIV/kg bw. Emesis was observed at doses of 0.25 mg/kg bw (in four out of six animals) and
at the highest dose of 0.5 mg/kg bw (in six out of six animals). According to the authors, the NOAEL
for emesis was 0.1 mg/kg bw per day and the LOAEL 0.25 mg/kg bw per day. The CONTAM
Panel decided that this study was the most appropriate for setting and acute HBGV for NIV.
Using a benchmark response (BMR) of 10% (BMD10) resulted in a benchmark dose 10% (BMD10)
total conﬁdence interval (BMDL10–BMDU10) of 0.14–0.23 mg NIV/kg bw, averaging the accepted
models. The CONTAM Panel used the BMDL10 value of 0.14 mg NIV/kg bw as a reference point for
characterising the acute toxicity of NIV (for details on the BMD modelling, see Appendix B).
10.2. Chronic effects
No new dose–response analysis was performed as there were no new relevant in vivo studies
identiﬁed.
11. Establishment of health based guidance values
11.1. Establishment of a group ARfD
The CONTAM Panel decided to use the BMDL10 of 0.14 mg NIV/kg bw derived for emetic response
in mink as a reference point for establishing a group ARfD for NIV. An UF of 10 for intraspecies
variability was applied. No interspecies variability factor was applied because humans were not
considered more sensitive than mink to the acute emetic effect of NIV, an assumption supported by
studies on emesis with emetine showing that similar doses of the compound are effective both in
humans and mink (Gordon, 1985; Zhang et al., 2006; Percie du Sert et al., 2012). Based on the above
data and considerations, an ARfD of 14 lg NIV/kg bw was established by the CONTAM Panel.
Because the phase II metabolite NIV3Glc is assumed to be hydrolysed to NIV after ingestion, it is
included in a group ARfD with the same molar potency as NIV.
Group HBGV for nivalenol and its modiﬁed forms
www.efsa.europa.eu/efsajournal 15 EFSA Journal 2017;15(4):4751
11.2. Establishment of a group TDI
The CONTAM Panel conﬁrmed the previously established TDI of 1.2 lg/kg bw based on a BMDL05
of 0.35 mg/kg bw per day and an UF of 300 (EFSA CONTAM Panel, 2013). Because the phase II
metabolite NIV3Glc is assumed to be hydrolysed to NIV after ingestion, it is included a group TDI with
the same molar potency as NIV.
12. Uncertainties
The CONTAM Panel identiﬁed several uncertainties in their evaluation of the appropriateness to set
a group HBGVs for NIV and its modiﬁed forms.
Upon reviewing new data, the TDI set for NIV in 2013 (EFSA CONTAM Panel, 2013) has been retained
because no new studies relevant for setting a chronic health based guidance value have been identiﬁed in
the period since then. Consequently, all uncertainties associated with establishment of the TDI as
described in the previous opinion (EFSA CONTAM Panel, 2013) are also valid for the present opinion.
An ARfD for NIV was established based on observations of emesis in an acute study with NIV in
mink. A total conﬁdence interval (BMDL10–BMDU10) of 0.14–0.23 mg NIV/kg bw was obtained using
model averaging in the dose–response analysis. The large dose spacing at the lower doses in these
studies and the small number of animals used resulted in a BMDL10 calculation associated with
considerable uncertainty. In addition, the steepness of the dose–response curves between two dose
groups add to the uncertainty.
In the absence of in vivo toxicokinetic and toxicity data on NIV3Glc, the CONTAM Panel assumed
the release of NIV upon ingestion and that therefore NIV3Glc should be included in the group HBGVs
with the same molar potency as NIV (i.e. 1).
The higher polarity of NIV compared with that of other trichothecenes leads to a more difﬁcult
analytical detection under the same chromatographic conditions. Further phase II metabolism would
increase the polarity and thus conjugates would be even more difﬁcult to analyse. It is, therefore,
likely that there are other phase II metabolites of NIV not yet identiﬁed.
12.1. Summary of uncertainties
In Table 2, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the source of uncertainty leads to over/underestimation
of the resulting risk.
The overall uncertainty associated with the inclusion of NIV3Glc into a group ARfD and a group TDI
in the present assessment is considered as high and it would rather overestimate than underestimate
any risk.
13. Conclusions
13.1. Introduction
NIV is a member of the type B group trichothecenes, which are tetracyclic sesquiterpenoids produced
by many fungal species infesting crop plants. In addition to NIV, produced by Fusarium species, plants
and fungi generate phase I and phase II metabolites. To date, the only phase I metabolite of NIV
identiﬁed is DE-NIV and the only phase II metabolite is NIV3Glc. It is expected that other conjugated
metabolites of NIV are formed in plants and fungi. Because of a lack of signiﬁcant toxicity DE-NIV was
not further considered in the assessment. Analytical methods (mainly based on LC–MS/MS) for NIV and
NIV3Glc are available. Due to high polarity of both compounds, recovery rates are often affected by
Table 2: Summary of the qualitative evaluation of the impact of uncertainties on the assessment
Sources of uncertainty Direction(a)
All uncertainties associated with setting the TDI for NIV in 2013 See EFSA CONTAM Panel (2013)
Assumption of complete cleavage of NIV3Glc to NIV +
Derivation of an ARfD based on a single study with mink +/
TDI: tolerable daily intake; NIV: nivalenol; NIV3Glc: nivalenol-3-glucoside.
(a): + = uncertainty with potential to cause overestimation of exposure/risk;  = uncertainty with potential to cause under-
estimation of exposure/risk, +/ = extent of potential over/underestimation might differ in direction.
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matrix effects which may lead to poor recovery. Standards and reference materials are not commercially
available for modiﬁed forms of NIV. The higher polarity of NIV compared to other trichothecenes leads
to a more difﬁcult analytical detection under the same chromatographic conditions. As further phase II
metabolism would increase the polarity, conjugates would be even more difﬁcult to analyse. It is
therefore likely that there are other phase II metabolites not yet identiﬁed.
13.2. Occurrence of modiﬁed forms of nivalenol
• NIV3Glc may occur in cereals amounting up to 50% of its parent form.
• The transfer of NIV from feed to food products of animal origin is expected to contribute only
marginally to human exposure.
13.3. Toxicokinetics of NIV and its modiﬁed forms
• Based on few studies available, the CONTAM Panel concluded that NIV is rapidly absorbed,
distributed and eliminated without accumulation.
• With the exception of DE-NIV, which is generated by microbiota in the rumen and also in the
gut of monogastric animals, no other NIV metabolites have been identiﬁed in mammals.
• No in vivo data are available on the absorption of NIV3Glc, but in vitro data indicate that it is
not absorbed. In vitro data suggest, however, that it is hydrolysed by bacteria in the
gastrointestinal tract and then absorbed as NIV.
13.4. Toxicity of NIV and its modiﬁed forms
• In vivo acute toxicity studies show that NIV has anorectic effects upon short term exposure in
mice and mink. Emetic events observed upon single oral and i.p. exposure to NIV in mink were
identiﬁed as the critical acute effect.
• In the previous opinion on NIV, it was concluded that there is no evidence that other toxic
effects occur at doses lower than those inducing immunotoxicity and haematotoxicity and that
there is no evidence for genotoxicity or carcinogenicity of NIV.
• De-epoxidation has been shown to markedly reduce the toxicity of trichothecenes such as DON
and T2. This mechanism of detoxiﬁcation also operates for NIV which has been shown in vitro.
• There is no toxicity information on NIV3Glc but it can be assumed that it is hydrolysed to and
absorbed in the lower intestinal tract as NIV.
13.5. Mode of action for toxicity
• NIV-induced anorexia correlates with increased plasma concentrations of the gut satiety
peptide cholecystokinin, suggesting a similar mode of action to that of other trichothecenes
such as DON.
• NIV targets the ribosome leading to an inhibition of protein, RNA and DNA synthesis. The
ribosome-binding activates MAPKs, which are important transducers of downstream signalling
events related to immune response and apoptosis.
• Rapidly proliferating tissues such as haematopoietic tissue are targets of NIV leading to leukopenia
and thrombocytopenia possibly due to induction of apoptosis (EFSA CONTAM Panel, 2013).
13.6. Acute dose-response analysis
• The CONTAM Panel selected the emetic effects of NIV for the acute hazard characterisation.
BMD analysis was performed on the incidence of emetic events in mink exposed to NIV.
• The BMD modelling using a BMR of 10% resulted in 90% benchmark dose conﬁdence interval
for the average model (BMDL10–BMDU10) of 0.14–0.23 mg NIV/kg bw NIV/kg bw per day.
13.7. Chronic dose–response analysis
• Because no new relevant data for derivation of a chronic HBGV were available, no dose–
response analysis was conducted and the BMDL05 of 0.35 mg NIV/kg bw per day based on a
reduction in white blood cell counts in a 90-day rat study as set previously (EFSA CONTAM
Panel, 2013) has been retained for the present assessment.
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13.7.1. Establishment of health based guidance values
13.7.2. Group Acute Reference dose for NIV and its modiﬁed forms
• Using the acute BMDL10 of 0.14 mg/kg bw per day for NIV and an UF of 10, for intraspecies
differences, an ARfD of 14 lg NIV/kg bw was established. No interspecies uncertainty factor was
applied since it was assumed that humans are not more sensitive towards the effect than mink.
• There are no data on acute emetic effects of NIV3Glc. It is assumed that it will be hydrolysed
in the lower intestine releasing NIV. Therefore, the Panel found it appropriate to include it in a
group ARfD with NIV with the same molar potency factor (i.e. 1)
13.7.3. Group Tolerable Daily Intake for NIV and its modiﬁed forms
• The CONTAM Panel noted that no new studies relevant for chronic hazard characterisation
were identiﬁed. Therefore, the current TDI of 1.2 lg NIV/kg bw has been retained.
• NIV3Glc can be hydrolysed to NIV after ingestion. Therefore, it can be included in a group TDI
with NIV.
14. Recommendations
• Because of the higher polarity of NIV and its conjugates compared with that of other
trichothecenes, the conditions used in the currently established analytical methods might not
be adequate for polar conjugates. Therefore, ﬁt-for-purpose methods should be designed for
an accurate detection of NIV and its modiﬁed forms to identify potential NIV metabolites not
yet detected. In addition, certiﬁed reference materials and standards for the modiﬁed forms of
NIV are needed.
• Studies on the toxicokinetics of modiﬁed forms of NIV, in particular NIV3Glc occurring in
plant-derived food items, should be conducted.
• The CONTAM Panel noted that FUS-X, which is reported in the literature as a mycotoxin on its
own, is also a precursor in the fungal biosynthesis of NIV and frequently co-occurs with NIV.
Therefore, it might be appropriate to perform a hazard characterisation of FUS-X and to
evaluate whether it should be included in group HGBVs with NIV.
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Abbreviations
AIC Akaike’s information criterion
ARfD acute reference dose
BMD benchmark dose
BMD10 the benchmark response of 10% resulted in a benchmark dose 10%
BMDL5 the 95th benchmark dose lower conﬁdence limit
BMDL10 the 90th benchmark dose lower conﬁdence limit
BMDU5 the 95th benchmark dose upper conﬁdence limit
BMDU10 the 95th benchmark dose upper conﬁdence limit
BMR benchmark response
BrdU bromodeoxyuridine
bw body weight
CAS Chemical Abstracts Service
CONTAM Panel EFSA Panel on Contaminants in the Food Chain
DE de-epoxy
DE-NIV de-epoxy-nivalenol
DON deoxynivalenol
DSPE dispersive solid-phase extraction
FAO Food and Agriculture Organization of the United Nations
FUS-X fusarenon-X
GC gas chromatography
Glc glucoside, glucose
GlcA glucuronic acid
HBGV health based guidance value
HO hydroxyl
HT2 HT2-toxin
LC–MS/MS liquid chromatography–tandem mass spectrometry
i.p. intraperitoneal
IC50 inhibitory concentration 50%
ICGN ICR-derived glomerulonephritis
ICR outbred mouse strain
IL interleukin
IUPAC International Union of Pure and Applied Chemistry
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LC liquid chromatography
LC-FLD liquid chromatography-ﬂuorescence detection
LC–MS/MS liquid chromatography–tandem mass spectrometry
LC-PDA liquid chromatography photodiode array detection
LOAEL lowest-observed-adverse-effect-level
NIV nivalenol
NIV3Glc nivalenol-3-glucoside
Man mannose
MAPK mitogen-activated protein synthesis kinase
ML maximum level
m.p. melting point
mRNA messenger RNA
MS mass spectrometry, mass spectrum
MS/MS tandem mass spectrometry
MW molecular weight
NMR nuclear magnetic resonance
NOAEL no-observed-adverse-effect-level
QuEChERS Quick, easy, cheap, effective, rugged and safe
RNA ribonucleic acid
T2 T2-toxin
TDI tolerable daily intake
TK6 thymidine kinase heterozygous cell line
UF uncertainty factor
WBC white blood cell
WHO World Health Organization
Xyl xylose
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Appendix A – Search for scientiﬁc literature on nivalenol
Table A.1: Search terms for web of science literature search
EFSA extensive review
Chemistry and analysis
Search terms TOPIC: (nivalenol) AND TOPIC: (chemistry OR analysis OR determination OR
detection OR identiﬁcation OR formation OR GC OR GC-MS OR HPLC OR LC-
MS OR ICP-MS)
Metabolism, Kinetics
Search terms TOPIC: (nivalenol) AND TOPIC (toxicokinetic* OR metabolism OR distribution
OR excretion OR absorption OR distribution OR biomarker OR mode of action
OR biotransformation OR elimination OR reduction OR detoxiﬁcation OR
extraction)
Toxicity
Search terms TOPIC: (nivalenol) AND TOPIC: (toxicity OR toxic* OR acute OR subacute OR
subchronic OR chronic OR mutagen* OR carcinogen* OR genotox* OR
reprotox* OR nephrotox* OR neurotox* OR hepatotox* OR immunotox* OR
haemotox* OR hemotox* OR cytotox* OR develop* toxicity OR thyroid OR
endocri* OR poisoning OR incidental poisoning OR rat OR mouse OR lab
animal OR animal*)
Epidemiology
Search terms TOPIC: (nivalenol) AND TOPIC: (biomarker OR biological marker OR case
study OR poisoning OR human poisoning OR human OR epidemiol*)
Date accessed 14 October 2016
Total Number after Removal
of duplicates
371
Number considered relevant 72
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Appendix B – Derivation of a benchmark dose for acute effects of nivalenol
B.1. Data description
The dose-dependent incidences of emesis upon administration of nivalenol (NIV) in mink in the
study from Wu et al. (2013) have been selected for derivation of a benchmark dose (BMD) for NIV
following the EFSA guidance on the use of the BMD (EFSA Scientiﬁc Committee, 2017). The ﬁndings
selected for deriving a BMD are described in Section 8.2.1 of this opinion.
Substance Dose (mg/kg bw) Animals showing emesis N Sex
NIV 0 0 6 F
0.05 0 6 F
0.10 0 6 F
0.25 4 6 F
0.5 6 6 F
bw: body weight; N: number of animals.
B.2. Selection of the BMR
The BMD is deﬁned as the dose that corresponds with an extra risk of 10% compared with the
background risk. The benchmark response (BMR) is the estimated risk corresponding with the BMD of
interest. A 90% conﬁdence interval around the BMD will be estimated, the lower bound is reported by
BMDL and the upper bound by BMDU.
B.3. Software used
Results are obtained using the R-package ‘bmdModeling’. Fitting BMD models is based on the R-
package Proast 61.3. Averaging results from multiple ﬁtted BMD models is based on the methodology
in Wheeler and Bailer (2008).
B.4. Results
Model
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Null 1 19.10 40.20 NA NA NA Yes –
Full 5 3.82 17.64 NA NA NA Yes –
Logistic 2 3.82 11.64 0.23 0.14 0.25 Yes Yes
Probit 2 16.48 36.96 0.14 NA NA No No
Log-
logistic
3 3.82 13.64 0.22 0.09 0.25 Yes Yes
Log-probit 3 3.82 13.64 0.20 0.09 0.25 Yes Yes
Weibull 3 3.82 13.64 0.22 NA NA Yes Yes
Gamma 3 3.82 13.64 0.20 0.08 0.23 Yes Yes
Two-stage 3 5.13 16.26 0.08 0.06 0.12 No No
B.5. Estimated model weights
Logistic Log-logistic Log-probit Weibull Gamma
0.4 0.15 0.15 0.15 0.15
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B.6. Conclusion
Given 1,000 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD
values and the BMDU is the 95th percentile.
The BMD is estimated based on the averaged response model which is a weighted average of the
accepted models’ response values. BMD = 0.22 mg/kg body weight (bw); BMDL = 0.14 mg/kg bw;
BMDU = 0.23 mg/kg bw.
Figure B.1: Averaged response model
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